NO318659B1 - Anvendelse av lipofile ekstrakter av rottene av Salvia miltiorrhyza Bunge for fremstilling av farmasoytiske sammensetninger til behandling av alkoholavhengighet. - Google Patents
Anvendelse av lipofile ekstrakter av rottene av Salvia miltiorrhyza Bunge for fremstilling av farmasoytiske sammensetninger til behandling av alkoholavhengighet. Download PDFInfo
- Publication number
- NO318659B1 NO318659B1 NO19975177A NO975177A NO318659B1 NO 318659 B1 NO318659 B1 NO 318659B1 NO 19975177 A NO19975177 A NO 19975177A NO 975177 A NO975177 A NO 975177A NO 318659 B1 NO318659 B1 NO 318659B1
- Authority
- NO
- Norway
- Prior art keywords
- alcohol
- treatment
- rats
- salvia
- extract
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 24
- 208000007848 Alcoholism Diseases 0.000 title claims abstract description 16
- 241001072909 Salvia Species 0.000 title claims abstract description 14
- 235000017276 Salvia Nutrition 0.000 title claims abstract description 14
- 241000612118 Samolus valerandi Species 0.000 title claims abstract description 7
- 201000007930 alcohol dependence Diseases 0.000 title claims description 10
- 241000700159 Rattus Species 0.000 title description 5
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- 238000002360 preparation method Methods 0.000 title description 2
- FEFAIBOZOKSLJR-UHFFFAOYSA-N Miltirone Chemical compound C1CCC(C)(C)C=2C1=C1C(=O)C(=O)C(C(C)C)=CC1=CC=2 FEFAIBOZOKSLJR-UHFFFAOYSA-N 0.000 claims abstract description 22
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 claims abstract description 10
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010013663 drug dependence Diseases 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 208000011117 substance-related disease Diseases 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229940084657 Benzodiazepine receptor inverse agonist Drugs 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000219781 Pueraria montana var. lobata Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000000755 benzodiazepine receptor inverse stimulating agent Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- BTZJQYVYGCCNHY-UHFFFAOYSA-N calcium;urea Chemical compound [Ca].NC(N)=O BTZJQYVYGCCNHY-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- -1 chloromethylene Chemical group 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 239000000399 hydroalcoholic extract Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Addiction (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI950958A IT1274481B (it) | 1995-05-12 | 1995-05-12 | Composizioni farmaceutiche per il trattamento della alcol-dipendenza |
| PCT/EP1996/001916 WO1996035441A1 (fr) | 1995-05-12 | 1996-05-08 | Compositions pharmaceutiques pour le traitement de l'alcoolisme |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO975177L NO975177L (no) | 1997-11-11 |
| NO975177D0 NO975177D0 (no) | 1997-11-11 |
| NO318659B1 true NO318659B1 (no) | 2005-04-25 |
Family
ID=11371582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19975177A NO318659B1 (no) | 1995-05-12 | 1997-11-11 | Anvendelse av lipofile ekstrakter av rottene av Salvia miltiorrhyza Bunge for fremstilling av farmasoytiske sammensetninger til behandling av alkoholavhengighet. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5904923A (fr) |
| EP (1) | EP0824356B1 (fr) |
| JP (1) | JP2955370B2 (fr) |
| KR (1) | KR100290029B1 (fr) |
| CN (1) | CN1066336C (fr) |
| AT (1) | ATE221384T1 (fr) |
| AU (1) | AU695010B2 (fr) |
| CA (1) | CA2220703C (fr) |
| DE (1) | DE69622704T2 (fr) |
| DK (1) | DK0824356T3 (fr) |
| ES (1) | ES2180783T3 (fr) |
| HK (1) | HK1009096A1 (fr) |
| IT (1) | IT1274481B (fr) |
| NO (1) | NO318659B1 (fr) |
| PT (1) | PT824356E (fr) |
| RU (1) | RU2153345C2 (fr) |
| WO (1) | WO1996035441A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2243005T3 (es) | 1997-07-30 | 2005-11-16 | Indena S.P.A. | Extracto de soja, proceso para su preparacion y composicion farmaceutica. |
| US5968746A (en) | 1997-11-26 | 1999-10-19 | Schneider; David R. | Method and apparatus for preserving human saliva for testing |
| US20020077352A1 (en) * | 2000-08-03 | 2002-06-20 | Sucher Nikolaus J. | N-methyl-D-aspartate receptor antagonists |
| CN1304723A (zh) * | 2001-01-16 | 2001-07-25 | 中山大学 | 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物 |
| US6852342B2 (en) * | 2002-03-26 | 2005-02-08 | Avoca, Inc. | Compounds for altering food intake in humans |
| WO2004058245A1 (fr) * | 2002-12-31 | 2004-07-15 | Zhongshan Univertsity | Utilisation de la tanshinone iia dans la prophylaxie ou le traitement de l'atherosclerose |
| US9827314B2 (en) * | 2003-12-08 | 2017-11-28 | Mars, Incorporated | Edible compositions which are adapted for use by a companion animal |
| JP2008538748A (ja) * | 2005-04-07 | 2008-11-06 | ハイシアム， インコーポレイテッド | 不安、物質乱用及び依存の予防のための改良型方法及び組成物 |
| GB201312205D0 (en) * | 2013-07-08 | 2013-08-21 | Univ Leuven Kath | Anticonvulsant activity of dan shen extracting compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1239281B (it) * | 1989-10-27 | 1993-10-19 | Indena Spa | Composizioni per la riduzione dei depositi di grasso superfluo a base di principi attivi di origine vegetale ad attivita' agonista dell'adenilato ciclasi o/e ad attivita' antifosfodiesterasica |
| US5204369A (en) * | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
-
1995
- 1995-05-12 IT ITMI950958A patent/IT1274481B/it active IP Right Grant
-
1996
- 1996-05-08 AU AU58153/96A patent/AU695010B2/en not_active Ceased
- 1996-05-08 CA CA002220703A patent/CA2220703C/fr not_active Expired - Fee Related
- 1996-05-08 ES ES96919706T patent/ES2180783T3/es not_active Expired - Lifetime
- 1996-05-08 RU RU97120507/14A patent/RU2153345C2/ru not_active IP Right Cessation
- 1996-05-08 PT PT96919706T patent/PT824356E/pt unknown
- 1996-05-08 EP EP96919706A patent/EP0824356B1/fr not_active Expired - Lifetime
- 1996-05-08 AT AT96919706T patent/ATE221384T1/de active
- 1996-05-08 JP JP8533745A patent/JP2955370B2/ja not_active Expired - Fee Related
- 1996-05-08 KR KR1019970708033A patent/KR100290029B1/ko not_active IP Right Cessation
- 1996-05-08 US US08/945,986 patent/US5904923A/en not_active Expired - Lifetime
- 1996-05-08 WO PCT/EP1996/001916 patent/WO1996035441A1/fr active IP Right Grant
- 1996-05-08 DE DE69622704T patent/DE69622704T2/de not_active Expired - Lifetime
- 1996-05-08 CN CN96193877A patent/CN1066336C/zh not_active Expired - Fee Related
- 1996-05-08 DK DK96919706T patent/DK0824356T3/da active
-
1997
- 1997-11-11 NO NO19975177A patent/NO318659B1/no not_active IP Right Cessation
-
1998
- 1998-08-21 HK HK98110082A patent/HK1009096A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR19990014692A (ko) | 1999-02-25 |
| CN1184429A (zh) | 1998-06-10 |
| NO975177L (no) | 1997-11-11 |
| NO975177D0 (no) | 1997-11-11 |
| EP0824356A1 (fr) | 1998-02-25 |
| AU5815396A (en) | 1996-11-29 |
| WO1996035441A1 (fr) | 1996-11-14 |
| DE69622704D1 (de) | 2002-09-05 |
| CN1066336C (zh) | 2001-05-30 |
| IT1274481B (it) | 1997-07-17 |
| DK0824356T3 (da) | 2002-11-25 |
| KR100290029B1 (ko) | 2001-05-15 |
| CA2220703C (fr) | 2001-07-24 |
| CA2220703A1 (fr) | 1996-11-14 |
| PT824356E (pt) | 2002-12-31 |
| JP2955370B2 (ja) | 1999-10-04 |
| RU2153345C2 (ru) | 2000-07-27 |
| HK1009096A1 (en) | 1999-05-28 |
| ES2180783T3 (es) | 2003-02-16 |
| US5904923A (en) | 1999-05-18 |
| ITMI950958A0 (it) | 1995-05-12 |
| AU695010B2 (en) | 1998-08-06 |
| DE69622704T2 (de) | 2003-04-03 |
| JPH10512583A (ja) | 1998-12-02 |
| ATE221384T1 (de) | 2002-08-15 |
| EP0824356B1 (fr) | 2002-07-31 |
| ITMI950958A1 (it) | 1996-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Patočka et al. | Biomedically relevant chemical constituents of Valeriana officinalis | |
| Bilia et al. | St. John's wort and depression: efficacy, safety and tolerability-an update | |
| KR100360674B1 (ko) | 치매 예방 및 치료제 조성물 | |
| Bhattacharya et al. | Effect of poly herbal formulation, EuMil, on neurochemical perturbations induced by chronic stress | |
| Kumar et al. | Hypoglycaemic effect of Helicteres isora bark extract in rats | |
| Germanò et al. | Hepatoprotective activity of Trichilia roka on carbon tetrachloride‐induced liver damage in rats | |
| NO318659B1 (no) | Anvendelse av lipofile ekstrakter av rottene av Salvia miltiorrhyza Bunge for fremstilling av farmasoytiske sammensetninger til behandling av alkoholavhengighet. | |
| Kassis et al. | Efficacy and safety assessments of Ferula assa-foetida L., traditionally used in Greco-Arab herbal medicine for enhancing male fertility, libido and erectile function | |
| KR101189108B1 (ko) | 황칠나무 추출물을 포함하는 남성 성기능 개선용 조성물 | |
| Tharakan et al. | Botanical therapies in sexual dysfunction | |
| CN100522193C (zh) | 构树果色素的用途 | |
| Furbee et al. | Life-threatening plant poisoning | |
| JP3091962B2 (ja) | テストステロン−５α−レダクターゼ阻害剤 | |
| KR100378735B1 (ko) | 원지로부터 유효성분의 추출·정제방법 및 그 추출물을함유한 치매치료용 생약 조성물 | |
| KR100523440B1 (ko) | 자생 식물로부터 얻은 비만 및 당뇨병 치료 추출물 | |
| CN112870290B (zh) | 一种祛斑解郁组合物及其制备方法 | |
| KR101822834B1 (ko) | 갱년기 증상 완화용 조성물 | |
| KR20040016579A (ko) | 비만 및 당뇨병 예방 및 치료효과를 보이는 자생식물 추출물 | |
| Shimada et al. | Choto-san prevents occurrence of stroke and prolongs life span in stroke-prone spontaneously hypertensive rats | |
| KR20010100548A (ko) | 지실로부터 유효성분의 추출·정제방법 및 그 추출물을함유한 치매치료용 생약 조성물 | |
| KR20040047617A (ko) | 니코틴제거 효과가 있는 조성물 및 그 제조 방법 | |
| NO316054B1 (no) | Anvendelse av forskolin eller ekstrakter inneholdende denne ved fremstilling av et medikament for behandling av alkoholavhengighet | |
| KR20040016578A (ko) | 항비만 및 항당뇨효과를 보이는 자생식물 추출물 | |
| Zhang et al. | The herbal medicine tian ma gou teng yen alters the development of high blood pressure in the spontaneously hypertensive rat | |
| WO2001039785A1 (fr) | Formulation contenant un extrait de feuille de cacahouete et son procede de preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |